IBD Diet and Medicines 2025: Latest Scientific Findings

Inflammatory bowel diseases (IBD), such as Crohn's disease and the S-shaped sigmoid colon that is attached to the rectum ulcerative colitis, chronic conditions that profoundly affect patients' daily lives. By 2025, science has reached the point where treatment is no longer about suppressing symptoms, but about complete healing of the gut lining and personalised precision medicine.

From Endomedix Gastroenterology Centre experts have summarised the latest dietary and medication guidelines.

The two faces of IBD: Crohn's and Colitis

Featured on	Crohn's disease (CD)	Ulcerative colitis (UC)
Affected section	Anywhere from the mouth to the rectum (often the end of the small intestine).	Only the colon and rectum.
Depth of inflammation	All layers of the intestinal wall are affected.	Only the innermost mucosa is affected.
Main symptoms	Right lower abdomen pain, weight loss, fistulas.	Bloody, pus-filled diarrhoea, an urgent stimulus.

The role of diet: what does science say in 2025?

There is no longer any question that nutrition actively influences inflammatory processes. Modern recommendations focus on:

1. Conscious use of fibre

Soluble fibres (oats, apples, carrots): They dissolve in water to form a gel, help improve stool consistency and feed beneficial gut bacteria.
Insoluble fibres (shell products, wheat bran): They should be avoided in the case of flare-ups or strictures, as they can mechanically irritate the inflamed intestinal tract.

2. Low FODMAP diet

Although originally developed to treat IBS, it is also highly effective for functional complaints (bloating, cramps) in IBD patients. It helps to limit fermentable carbohydrates.

3. Nutrient supplementation

Monitoring levels is critical because of absorption problems:

Vitamin D and Calcium: For the prevention of osteoporosis (especially with steroid treatment).
Vitamin B12 and Iron: Against anaemia and fatigue.

Modern drug therapies

Besides conventional agents (5-ASA, steroids), the year 2025 is the year for targeted molecules:

Biological therapies: Proteins that block inflammatory signalling (e.g. anti-TNF, integrin inhibitors, interleukin inhibitors).
JAK inhibitors: A new generation of oral „small molecule” drugs that stop inflammation at the cellular level (mainly in ulcerative colitis).
Combined therapies: The direction of research is the simultaneous use of agents with different mechanisms of action for higher remission rates.

What does the near future hold?

Research is currently underway in the microbiome-based treatments (e.g. fine-tuning faecal transplantation) and precision medicine focus on. The aim of the latter is to use genetic and biomarkers to predict on the first day which drug will be effective in a given patient, avoiding unnecessary trials.